| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medulloblastoma | 55 | 2024 | 385 | 6.660 |
Why?
|
| Brain Neoplasms | 70 | 2026 | 1300 | 6.350 |
Why?
|
| Cerebellar Neoplasms | 48 | 2024 | 321 | 5.860 |
Why?
|
| Proton Therapy | 27 | 2025 | 157 | 5.640 |
Why?
|
| Retinoblastoma | 20 | 2023 | 87 | 5.040 |
Why?
|
| Retinal Neoplasms | 18 | 2023 | 74 | 4.520 |
Why?
|
| Glioma | 26 | 2025 | 500 | 4.160 |
Why?
|
| Ependymoma | 13 | 2026 | 153 | 3.470 |
Why?
|
| Craniospinal Irradiation | 14 | 2024 | 60 | 3.270 |
Why?
|
| Child | 190 | 2025 | 26332 | 2.240 |
Why?
|
| Kidney Neoplasms | 16 | 2023 | 453 | 2.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 29 | 2023 | 1357 | 2.150 |
Why?
|
| Wilms Tumor | 13 | 2023 | 120 | 2.130 |
Why?
|
| Child, Preschool | 132 | 2025 | 15066 | 1.900 |
Why?
|
| Radiotherapy, Intensity-Modulated | 9 | 2017 | 100 | 1.830 |
Why?
|
| Photons | 6 | 2021 | 64 | 1.580 |
Why?
|
| Hearing Loss | 9 | 2024 | 211 | 1.350 |
Why?
|
| Infant | 84 | 2025 | 13332 | 1.330 |
Why?
|
| Adolescent | 109 | 2025 | 21008 | 1.280 |
Why?
|
| Optic Nerve Glioma | 3 | 2021 | 21 | 1.280 |
Why?
|
| Humans | 238 | 2026 | 131967 | 1.210 |
Why?
|
| Radiation Injuries | 10 | 2022 | 147 | 1.200 |
Why?
|
| Craniopharyngioma | 4 | 2023 | 34 | 1.180 |
Why?
|
| Neurosurgical Procedures | 7 | 2025 | 317 | 1.160 |
Why?
|
| Vincristine | 13 | 2022 | 194 | 1.160 |
Why?
|
| Central Nervous System Neoplasms | 9 | 2024 | 208 | 1.150 |
Why?
|
| Protons | 10 | 2023 | 100 | 1.130 |
Why?
|
| Pituitary Neoplasms | 4 | 2023 | 78 | 1.120 |
Why?
|
| Neoplasm Recurrence, Local | 14 | 2024 | 1281 | 1.110 |
Why?
|
| Male | 162 | 2026 | 65357 | 1.060 |
Why?
|
| Cochlea | 3 | 2024 | 88 | 1.040 |
Why?
|
| Radiotherapy Dosage | 17 | 2023 | 216 | 1.040 |
Why?
|
| Soft Tissue Neoplasms | 5 | 2021 | 128 | 1.010 |
Why?
|
| Bone Neoplasms | 10 | 2015 | 452 | 1.010 |
Why?
|
| Cisplatin | 12 | 2024 | 286 | 1.010 |
Why?
|
| Female | 157 | 2026 | 71316 | 0.990 |
Why?
|
| Brain Stem Neoplasms | 7 | 2022 | 41 | 0.980 |
Why?
|
| Antineoplastic Agents | 16 | 2024 | 1812 | 0.940 |
Why?
|
| Biomarkers, Tumor | 16 | 2023 | 1618 | 0.930 |
Why?
|
| Cognition | 9 | 2023 | 845 | 0.920 |
Why?
|
| Neurologists | 1 | 2025 | 25 | 0.900 |
Why?
|
| Combined Modality Therapy | 28 | 2023 | 1261 | 0.900 |
Why?
|
| Chemotherapy, Adjuvant | 11 | 2019 | 393 | 0.880 |
Why?
|
| Neuroectodermal Tumors, Primitive | 6 | 2022 | 45 | 0.860 |
Why?
|
| Follow-Up Studies | 28 | 2025 | 5298 | 0.850 |
Why?
|
| Carboplatin | 7 | 2020 | 80 | 0.850 |
Why?
|
| Neoplasms | 7 | 2024 | 2965 | 0.820 |
Why?
|
| Cranial Irradiation | 6 | 2010 | 73 | 0.800 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2023 | 155 | 0.800 |
Why?
|
| Retrospective Studies | 47 | 2025 | 17703 | 0.780 |
Why?
|
| Osteosarcoma | 9 | 2015 | 268 | 0.780 |
Why?
|
| Astrocytoma | 8 | 2025 | 102 | 0.760 |
Why?
|
| Disease-Free Survival | 19 | 2020 | 910 | 0.750 |
Why?
|
| Treatment Outcome | 43 | 2025 | 13011 | 0.740 |
Why?
|
| DNA Methylation | 12 | 2022 | 1093 | 0.710 |
Why?
|
| Hypothyroidism | 2 | 2021 | 78 | 0.710 |
Why?
|
| Prognosis | 28 | 2025 | 4961 | 0.710 |
Why?
|
| Sarcoma | 2 | 2015 | 211 | 0.690 |
Why?
|
| Fever | 1 | 2024 | 312 | 0.690 |
Why?
|
| Tenon Capsule | 1 | 2020 | 1 | 0.660 |
Why?
|
| Neurofibromatosis 1 | 3 | 2019 | 67 | 0.650 |
Why?
|
| Cancer Survivors | 6 | 2021 | 267 | 0.630 |
Why?
|
| Glioblastoma | 7 | 2023 | 347 | 0.620 |
Why?
|
| Dacarbazine | 4 | 2015 | 94 | 0.580 |
Why?
|
| Nose Neoplasms | 2 | 2015 | 31 | 0.560 |
Why?
|
| Survival Rate | 18 | 2024 | 2154 | 0.550 |
Why?
|
| Supratentorial Neoplasms | 3 | 2021 | 40 | 0.540 |
Why?
|
| Medical Oncology | 4 | 2023 | 238 | 0.540 |
Why?
|
| Organ Sparing Treatments | 1 | 2018 | 43 | 0.530 |
Why?
|
| Radiotherapy, Conformal | 7 | 2012 | 51 | 0.520 |
Why?
|
| Prospective Studies | 20 | 2023 | 6522 | 0.510 |
Why?
|
| Appendiceal Neoplasms | 1 | 2017 | 22 | 0.510 |
Why?
|
| Global Health | 2 | 2021 | 633 | 0.500 |
Why?
|
| Neuroendocrine Tumors | 1 | 2017 | 59 | 0.490 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2015 | 3 | 0.480 |
Why?
|
| Young Adult | 31 | 2024 | 10108 | 0.470 |
Why?
|
| Pediatrics | 2 | 2025 | 1239 | 0.470 |
Why?
|
| Nasal Cavity | 1 | 2015 | 55 | 0.450 |
Why?
|
| Thoracic Wall | 1 | 2015 | 41 | 0.450 |
Why?
|
| Cyclophosphamide | 9 | 2021 | 441 | 0.450 |
Why?
|
| Germ-Line Mutation | 5 | 2021 | 375 | 0.450 |
Why?
|
| Nephroma, Mesoblastic | 2 | 2009 | 9 | 0.440 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2015 | 246 | 0.440 |
Why?
|
| Anti-Bacterial Agents | 2 | 2024 | 2578 | 0.440 |
Why?
|
| Neoplasm Grading | 6 | 2024 | 277 | 0.440 |
Why?
|
| Rhabdomyosarcoma | 4 | 2021 | 228 | 0.420 |
Why?
|
| Adaptation, Psychological | 3 | 2024 | 437 | 0.410 |
Why?
|
| Nephrectomy | 5 | 2023 | 175 | 0.410 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2025 | 3928 | 0.410 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2025 | 68 | 0.410 |
Why?
|
| Hamartoma Syndrome, Multiple | 2 | 2011 | 20 | 0.410 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2021 | 1078 | 0.400 |
Why?
|
| Intelligence | 5 | 2023 | 105 | 0.400 |
Why?
|
| Infusions, Intra-Arterial | 3 | 2023 | 19 | 0.390 |
Why?
|
| Mutism | 2 | 2024 | 29 | 0.390 |
Why?
|
| Chemoradiotherapy | 4 | 2024 | 120 | 0.380 |
Why?
|
| Infant, Newborn | 21 | 2021 | 8604 | 0.380 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 3 | 2021 | 52 | 0.370 |
Why?
|
| Neoplasm Seeding | 2 | 2017 | 10 | 0.370 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2012 | 48 | 0.370 |
Why?
|
| Vitreous Body | 2 | 2017 | 56 | 0.370 |
Why?
|
| Neonatology | 1 | 2012 | 60 | 0.350 |
Why?
|
| Disease Progression | 11 | 2025 | 2226 | 0.340 |
Why?
|
| Teratoma | 3 | 2021 | 124 | 0.340 |
Why?
|
| Brain Stem | 4 | 2022 | 112 | 0.340 |
Why?
|
| Rhabdoid Tumor | 4 | 2021 | 48 | 0.340 |
Why?
|
| Liver Neoplasms | 4 | 2016 | 1394 | 0.330 |
Why?
|
| Upper Extremity | 1 | 2011 | 52 | 0.330 |
Why?
|
| Arteriovenous Malformations | 1 | 2011 | 47 | 0.330 |
Why?
|
| Survivors | 5 | 2022 | 352 | 0.330 |
Why?
|
| Adult | 45 | 2024 | 31734 | 0.330 |
Why?
|
| Neoadjuvant Therapy | 3 | 2025 | 407 | 0.320 |
Why?
|
| Melphalan | 2 | 2023 | 44 | 0.320 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 125 | 0.320 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2022 | 93 | 0.320 |
Why?
|
| Survival Analysis | 13 | 2021 | 1522 | 0.310 |
Why?
|
| Developing Countries | 3 | 2024 | 306 | 0.310 |
Why?
|
| Meningeal Neoplasms | 2 | 2012 | 208 | 0.310 |
Why?
|
| Eye Enucleation | 8 | 2019 | 34 | 0.310 |
Why?
|
| Neoplasm Staging | 9 | 2023 | 1325 | 0.310 |
Why?
|
| Neoplasms, Radiation-Induced | 3 | 2018 | 76 | 0.310 |
Why?
|
| Fibrosarcoma | 1 | 2009 | 24 | 0.300 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 388 | 0.300 |
Why?
|
| Antineoplastic Agents, Alkylating | 6 | 2021 | 98 | 0.300 |
Why?
|
| Sirolimus | 1 | 2011 | 231 | 0.300 |
Why?
|
| Leukemia | 1 | 2012 | 375 | 0.290 |
Why?
|
| Neoplasms, Second Primary | 2 | 2021 | 143 | 0.290 |
Why?
|
| Cognition Disorders | 7 | 2019 | 565 | 0.290 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2021 | 1000 | 0.280 |
Why?
|
| Hepatoblastoma | 3 | 2016 | 188 | 0.280 |
Why?
|
| Feasibility Studies | 5 | 2023 | 838 | 0.280 |
Why?
|
| Radiation Dosage | 2 | 2019 | 137 | 0.280 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 3 | 2021 | 41 | 0.270 |
Why?
|
| Incidence | 12 | 2021 | 3352 | 0.270 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2007 | 7 | 0.270 |
Why?
|
| Risk Factors | 23 | 2024 | 10998 | 0.260 |
Why?
|
| Cognitive Dysfunction | 2 | 2023 | 355 | 0.260 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2023 | 62 | 0.260 |
Why?
|
| Amifostine | 3 | 2014 | 13 | 0.260 |
Why?
|
| Thymidine Kinase | 2 | 2010 | 89 | 0.260 |
Why?
|
| Recurrence | 6 | 2023 | 1487 | 0.250 |
Why?
|
| Neoplastic Stem Cells | 4 | 2016 | 331 | 0.250 |
Why?
|
| Diagnosis, Differential | 7 | 2021 | 1916 | 0.250 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2010 | 2123 | 0.240 |
Why?
|
| Meningioma | 1 | 2008 | 137 | 0.240 |
Why?
|
| Ophthalmic Artery | 2 | 2023 | 17 | 0.240 |
Why?
|
| Head and Neck Neoplasms | 5 | 2021 | 634 | 0.240 |
Why?
|
| Mutation | 11 | 2023 | 6200 | 0.240 |
Why?
|
| Lung Neoplasms | 4 | 2021 | 1545 | 0.240 |
Why?
|
| DNA, Neoplasm | 5 | 2016 | 287 | 0.240 |
Why?
|
| Vision Disorders | 2 | 2021 | 197 | 0.230 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2010 | 1264 | 0.230 |
Why?
|
| Ganciclovir | 1 | 2005 | 102 | 0.230 |
Why?
|
| Hedgehog Proteins | 3 | 2019 | 203 | 0.230 |
Why?
|
| Adenoviruses, Human | 1 | 2005 | 97 | 0.230 |
Why?
|
| Rhombencephalon | 1 | 2026 | 68 | 0.230 |
Why?
|
| Pilot Projects | 6 | 2022 | 1457 | 0.220 |
Why?
|
| Age Factors | 7 | 2024 | 2869 | 0.220 |
Why?
|
| Etoposide | 3 | 2020 | 117 | 0.220 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2015 | 102 | 0.220 |
Why?
|
| Anilides | 2 | 2015 | 53 | 0.210 |
Why?
|
| Neoplasm, Residual | 4 | 2021 | 137 | 0.210 |
Why?
|
| Radiotherapy | 2 | 2018 | 120 | 0.210 |
Why?
|
| Lymphopenia | 1 | 2024 | 34 | 0.210 |
Why?
|
| Androgens | 1 | 2026 | 272 | 0.210 |
Why?
|
| Intelligence Tests | 3 | 2022 | 63 | 0.200 |
Why?
|
| Anaplasia | 2 | 2022 | 7 | 0.200 |
Why?
|
| Texas | 7 | 2021 | 3629 | 0.200 |
Why?
|
| Registries | 6 | 2022 | 1598 | 0.200 |
Why?
|
| Gangliosides | 1 | 2024 | 74 | 0.200 |
Why?
|
| Hearing | 3 | 2018 | 61 | 0.200 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 2019 | 155 | 0.200 |
Why?
|
| Gene Amplification | 4 | 2009 | 228 | 0.200 |
Why?
|
| DNA-Binding Proteins | 4 | 2021 | 1964 | 0.200 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2023 | 24 | 0.200 |
Why?
|
| Immunohistochemistry | 10 | 2016 | 1610 | 0.200 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2023 | 3425 | 0.200 |
Why?
|
| Thrombocythemia, Essential | 2 | 1995 | 33 | 0.200 |
Why?
|
| Pyridines | 2 | 2015 | 260 | 0.190 |
Why?
|
| Preoperative Care | 1 | 2025 | 357 | 0.190 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 41 | 0.190 |
Why?
|
| Ganglioglioma | 2 | 2007 | 21 | 0.190 |
Why?
|
| Treatment Failure | 5 | 2021 | 353 | 0.190 |
Why?
|
| Genetic Testing | 4 | 2019 | 1101 | 0.180 |
Why?
|
| Quinazolines | 2 | 1995 | 181 | 0.180 |
Why?
|
| Clinical Trials as Topic | 4 | 2021 | 1141 | 0.180 |
Why?
|
| Symporters | 1 | 2022 | 75 | 0.180 |
Why?
|
| Topotecan | 3 | 2007 | 48 | 0.180 |
Why?
|
| Survivorship | 1 | 2022 | 46 | 0.180 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 215 | 0.180 |
Why?
|
| DNA Mutational Analysis | 8 | 2021 | 803 | 0.180 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 11 | 2015 | 1236 | 0.180 |
Why?
|
| Fourth Ventricle | 1 | 2021 | 9 | 0.180 |
Why?
|
| MyoD Protein | 1 | 2021 | 22 | 0.170 |
Why?
|
| Gene Expression Profiling | 7 | 2021 | 1841 | 0.170 |
Why?
|
| Cerebellar Diseases | 1 | 2022 | 78 | 0.170 |
Why?
|
| Embolism, Air | 1 | 2001 | 22 | 0.170 |
Why?
|
| Adrenal Insufficiency | 1 | 2021 | 31 | 0.170 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2021 | 9 | 0.170 |
Why?
|
| Oncolytic Viruses | 2 | 2013 | 75 | 0.170 |
Why?
|
| Doxorubicin | 4 | 2017 | 301 | 0.170 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 1995 | 274 | 0.170 |
Why?
|
| Social Class | 2 | 2019 | 212 | 0.170 |
Why?
|
| Neoplasm Transplantation | 3 | 2020 | 361 | 0.170 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 59 | 0.170 |
Why?
|
| Transcription Factor RelA | 1 | 2021 | 54 | 0.170 |
Why?
|
| Oncolytic Virotherapy | 2 | 2013 | 90 | 0.170 |
Why?
|
| Brain | 8 | 2023 | 3247 | 0.170 |
Why?
|
| Language Development Disorders | 1 | 2022 | 178 | 0.170 |
Why?
|
| Gadolinium | 1 | 2021 | 112 | 0.160 |
Why?
|
| WAGR Syndrome | 1 | 2020 | 7 | 0.160 |
Why?
|
| Mice, SCID | 7 | 2020 | 579 | 0.160 |
Why?
|
| Camptothecin | 4 | 2006 | 78 | 0.160 |
Why?
|
| Thyroid Neoplasms | 1 | 2023 | 248 | 0.160 |
Why?
|
| Capecitabine | 2 | 2017 | 19 | 0.160 |
Why?
|
| Audiometry, Pure-Tone | 2 | 2018 | 24 | 0.160 |
Why?
|
| Early Diagnosis | 1 | 2021 | 192 | 0.160 |
Why?
|
| Endpoint Determination | 1 | 2020 | 57 | 0.160 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2020 | 25 | 0.160 |
Why?
|
| Antiviral Agents | 1 | 2005 | 813 | 0.160 |
Why?
|
| Catheterization, Central Venous | 1 | 2001 | 141 | 0.160 |
Why?
|
| Health Status Disparities | 2 | 2021 | 277 | 0.160 |
Why?
|
| Pinealoma | 1 | 2019 | 20 | 0.160 |
Why?
|
| Kidney | 3 | 2022 | 1304 | 0.160 |
Why?
|
| Disease Models, Animal | 8 | 2026 | 4684 | 0.160 |
Why?
|
| Pineal Gland | 1 | 2019 | 21 | 0.160 |
Why?
|
| Dactinomycin | 3 | 2022 | 48 | 0.160 |
Why?
|
| Antigens, CD | 2 | 2014 | 418 | 0.160 |
Why?
|
| DNA Polymerase II | 1 | 2019 | 19 | 0.160 |
Why?
|
| Global Burden of Disease | 1 | 2019 | 33 | 0.150 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 28 | 0.150 |
Why?
|
| Brain Edema | 1 | 2020 | 65 | 0.150 |
Why?
|
| Glycoproteins | 2 | 2014 | 349 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2021 | 178 | 0.150 |
Why?
|
| Biopsy | 3 | 2021 | 1252 | 0.150 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 360 | 0.150 |
Why?
|
| Sarcoma, Clear Cell | 2 | 2015 | 21 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2016 | 2013 | 0.150 |
Why?
|
| Mice | 15 | 2026 | 18504 | 0.150 |
Why?
|
| Escherichia coli Infections | 1 | 2001 | 195 | 0.150 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 275 | 0.150 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2019 | 299 | 0.150 |
Why?
|
| Scoliosis | 1 | 2021 | 145 | 0.150 |
Why?
|
| Genetic Counseling | 1 | 2021 | 238 | 0.150 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 74 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2013 | 754 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 502 | 0.150 |
Why?
|
| Bronchial Neoplasms | 1 | 2019 | 16 | 0.150 |
Why?
|
| Steroids | 1 | 2020 | 172 | 0.150 |
Why?
|
| Pulmonary Embolism | 1 | 2001 | 191 | 0.150 |
Why?
|
| Precancerous Conditions | 1 | 2022 | 283 | 0.150 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 1999 | 42 | 0.150 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2019 | 81 | 0.150 |
Why?
|
| Neoplasm Proteins | 3 | 2012 | 677 | 0.150 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2021 | 232 | 0.150 |
Why?
|
| Radiation Tolerance | 2 | 2018 | 60 | 0.140 |
Why?
|
| Carcinoid Tumor | 1 | 2019 | 24 | 0.140 |
Why?
|
| Anxiety | 1 | 2025 | 1030 | 0.140 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 3 | 1998 | 52 | 0.140 |
Why?
|
| Pyrazoles | 1 | 2021 | 359 | 0.140 |
Why?
|
| Quality of Life | 3 | 2023 | 2116 | 0.140 |
Why?
|
| Peptides | 2 | 2014 | 834 | 0.140 |
Why?
|
| Blood Proteins | 2 | 2010 | 140 | 0.140 |
Why?
|
| Memory, Short-Term | 1 | 2019 | 141 | 0.140 |
Why?
|
| Umbilicus | 1 | 1998 | 14 | 0.140 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1999 | 85 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2021 | 445 | 0.140 |
Why?
|
| Abdominal Neoplasms | 1 | 1998 | 31 | 0.140 |
Why?
|
| Rothmund-Thomson Syndrome | 3 | 2003 | 48 | 0.140 |
Why?
|
| Transcription Factors | 2 | 2021 | 2442 | 0.140 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2021 | 545 | 0.140 |
Why?
|
| Administration, Oral | 4 | 2017 | 710 | 0.140 |
Why?
|
| Visual Acuity | 1 | 2021 | 535 | 0.140 |
Why?
|
| Beckwith-Wiedemann Syndrome | 1 | 1997 | 16 | 0.130 |
Why?
|
| Tablets | 2 | 2017 | 38 | 0.130 |
Why?
|
| Myofibroma | 1 | 2017 | 9 | 0.130 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 56 | 0.130 |
Why?
|
| Poverty | 1 | 2021 | 456 | 0.130 |
Why?
|
| Tumor Burden | 4 | 2021 | 239 | 0.130 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 409 | 0.130 |
Why?
|
| Bacteremia | 1 | 2001 | 428 | 0.130 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2016 | 19 | 0.130 |
Why?
|
| Premature Birth | 1 | 2021 | 414 | 0.130 |
Why?
|
| Neuroimaging | 1 | 2020 | 406 | 0.130 |
Why?
|
| Depression | 1 | 2025 | 1352 | 0.120 |
Why?
|
| Proteome | 2 | 2010 | 288 | 0.120 |
Why?
|
| Chromosome Fragility | 1 | 1996 | 13 | 0.120 |
Why?
|
| Colectomy | 1 | 2017 | 88 | 0.120 |
Why?
|
| Appendectomy | 1 | 2017 | 88 | 0.120 |
Why?
|
| Incidental Findings | 1 | 2017 | 125 | 0.120 |
Why?
|
| Executive Function | 1 | 2017 | 136 | 0.120 |
Why?
|
| Pancytopenia | 1 | 1996 | 40 | 0.120 |
Why?
|
| RNA, Messenger | 4 | 2015 | 2573 | 0.120 |
Why?
|
| Germinoma | 1 | 2016 | 31 | 0.120 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2014 | 100 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 62 | 0.120 |
Why?
|
| Femoral Neoplasms | 1 | 2015 | 8 | 0.120 |
Why?
|
| Stem Cell Transplantation | 2 | 2015 | 236 | 0.120 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 1996 | 45 | 0.120 |
Why?
|
| Metastasectomy | 1 | 2015 | 11 | 0.120 |
Why?
|
| von Willebrand Factor | 3 | 1998 | 192 | 0.120 |
Why?
|
| Attention | 1 | 2017 | 198 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2014 | 1626 | 0.120 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2015 | 13 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2008 | 139 | 0.120 |
Why?
|
| Transplantation, Heterologous | 2 | 2014 | 261 | 0.120 |
Why?
|
| Appendicitis | 1 | 2017 | 132 | 0.120 |
Why?
|
| Time Factors | 7 | 2021 | 6285 | 0.110 |
Why?
|
| Immediate-Early Proteins | 1 | 2015 | 57 | 0.110 |
Why?
|
| Drug Therapy, Combination | 3 | 2015 | 1173 | 0.110 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2015 | 6 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2020 | 1224 | 0.110 |
Why?
|
| Enterotoxins | 3 | 1991 | 77 | 0.110 |
Why?
|
| Viral Matrix Proteins | 1 | 2015 | 108 | 0.110 |
Why?
|
| Models, Genetic | 1 | 2018 | 752 | 0.110 |
Why?
|
| Insurance Coverage | 1 | 2016 | 117 | 0.110 |
Why?
|
| Methotrexate | 2 | 2015 | 344 | 0.110 |
Why?
|
| Protein Kinase C beta | 1 | 2014 | 17 | 0.110 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2011 | 62 | 0.110 |
Why?
|
| Sacrum | 2 | 2015 | 28 | 0.110 |
Why?
|
| Mass Screening | 1 | 2021 | 825 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 111 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 1998 | 265 | 0.110 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2015 | 89 | 0.110 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2014 | 28 | 0.110 |
Why?
|
| Induction Chemotherapy | 1 | 2015 | 55 | 0.110 |
Why?
|
| Superantigens | 2 | 1991 | 20 | 0.110 |
Why?
|
| Health Personnel | 1 | 2020 | 550 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2021 | 895 | 0.110 |
Why?
|
| Antigens, CD1d | 1 | 2014 | 21 | 0.110 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 1419 | 0.110 |
Why?
|
| Prenatal Diagnosis | 2 | 2012 | 653 | 0.110 |
Why?
|
| Histiocytosis, Sinus | 1 | 1995 | 35 | 0.110 |
Why?
|
| Genetic Vectors | 2 | 2010 | 907 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2015 | 2863 | 0.110 |
Why?
|
| CHARGE Syndrome | 1 | 2014 | 8 | 0.110 |
Why?
|
| Animals | 17 | 2026 | 34460 | 0.110 |
Why?
|
| Radiography | 4 | 2015 | 762 | 0.100 |
Why?
|
| Pneumonectomy | 1 | 2015 | 151 | 0.100 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 132 | 0.100 |
Why?
|
| Spinal Fusion | 1 | 2015 | 118 | 0.100 |
Why?
|
| Genetic Markers | 1 | 2015 | 605 | 0.100 |
Why?
|
| Protective Agents | 1 | 2014 | 36 | 0.100 |
Why?
|
| Bacterial Toxins | 2 | 1991 | 171 | 0.100 |
Why?
|
| Neuropsychological Tests | 3 | 2024 | 998 | 0.100 |
Why?
|
| Infusions, Intravenous | 6 | 2007 | 551 | 0.100 |
Why?
|
| Indoles | 1 | 2014 | 205 | 0.100 |
Why?
|
| Picornaviridae | 1 | 2013 | 19 | 0.100 |
Why?
|
| Phosphoproteins | 1 | 2015 | 430 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 639 | 0.100 |
Why?
|
| Natural Killer T-Cells | 1 | 2014 | 95 | 0.100 |
Why?
|
| Cohort Studies | 6 | 2019 | 5122 | 0.100 |
Why?
|
| Endocrine System Diseases | 1 | 2013 | 43 | 0.100 |
Why?
|
| Carcinosarcoma | 1 | 2012 | 12 | 0.100 |
Why?
|
| Deoxycytidine | 1 | 2013 | 82 | 0.100 |
Why?
|
| Predictive Value of Tests | 5 | 2021 | 2308 | 0.100 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2012 | 17 | 0.100 |
Why?
|
| Fluorouracil | 1 | 2013 | 134 | 0.100 |
Why?
|
| Pons | 1 | 1993 | 34 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2014 | 659 | 0.090 |
Why?
|
| Affective Symptoms | 1 | 2013 | 64 | 0.090 |
Why?
|
| Demyelinating Diseases | 1 | 1993 | 68 | 0.090 |
Why?
|
| Macrophages | 2 | 2014 | 663 | 0.090 |
Why?
|
| Forkhead Transcription Factors | 2 | 2022 | 372 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2015 | 955 | 0.090 |
Why?
|
| Epoxide Hydrolases | 1 | 2012 | 36 | 0.090 |
Why?
|
| Medical Records | 1 | 2013 | 181 | 0.090 |
Why?
|
| Area Under Curve | 4 | 2007 | 320 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 462 | 0.090 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 710 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2023 | 934 | 0.090 |
Why?
|
| Sarcoma, Ewing | 1 | 2013 | 117 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 602 | 0.090 |
Why?
|
| Gene Dosage | 3 | 2009 | 439 | 0.090 |
Why?
|
| Genes, Retinoblastoma | 1 | 2011 | 22 | 0.090 |
Why?
|
| Adenosine Triphosphatases | 2 | 2003 | 188 | 0.090 |
Why?
|
| HLA-DR Antigens | 1 | 1991 | 70 | 0.090 |
Why?
|
| Risk Assessment | 7 | 2021 | 3708 | 0.090 |
Why?
|
| Retinoblastoma Protein | 1 | 2011 | 78 | 0.090 |
Why?
|
| United Kingdom | 1 | 2012 | 255 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 188 | 0.090 |
Why?
|
| Ear | 1 | 2011 | 27 | 0.090 |
Why?
|
| Syndrome | 3 | 2022 | 1170 | 0.090 |
Why?
|
| Procarbazine | 2 | 2006 | 11 | 0.090 |
Why?
|
| DNA Helicases | 2 | 2003 | 235 | 0.090 |
Why?
|
| Repressor Proteins | 1 | 2015 | 781 | 0.080 |
Why?
|
| Central Nervous System | 1 | 2013 | 286 | 0.080 |
Why?
|
| Lymphatic Metastasis | 2 | 2009 | 433 | 0.080 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2010 | 16 | 0.080 |
Why?
|
| Lymph Nodes | 2 | 2008 | 377 | 0.080 |
Why?
|
| Myosarcoma | 1 | 2010 | 2 | 0.080 |
Why?
|
| Case-Control Studies | 5 | 2021 | 3453 | 0.080 |
Why?
|
| Social Adjustment | 2 | 2022 | 79 | 0.080 |
Why?
|
| Chemokines, CXC | 1 | 2010 | 36 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 1998 | 1001 | 0.080 |
Why?
|
| Rare Diseases | 1 | 2012 | 209 | 0.080 |
Why?
|
| Disease Susceptibility | 2 | 2022 | 283 | 0.080 |
Why?
|
| Organs at Risk | 1 | 2010 | 41 | 0.080 |
Why?
|
| Hodgkin Disease | 1 | 1993 | 312 | 0.080 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 151 | 0.080 |
Why?
|
| Anticonvulsants | 2 | 2003 | 391 | 0.080 |
Why?
|
| Epigenomics | 2 | 2021 | 186 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1406 | 0.080 |
Why?
|
| Injections, Intravenous | 3 | 2017 | 242 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2011 | 432 | 0.080 |
Why?
|
| Genomics | 3 | 2021 | 1630 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2007 | 147 | 0.070 |
Why?
|
| Cell Proliferation | 3 | 2026 | 2483 | 0.070 |
Why?
|
| Nervous System Diseases | 1 | 2013 | 403 | 0.070 |
Why?
|
| Staphylococcus aureus | 2 | 1991 | 485 | 0.070 |
Why?
|
| Gamma Rays | 1 | 2008 | 43 | 0.070 |
Why?
|
| Leg | 1 | 2009 | 124 | 0.070 |
Why?
|
| RNA-Binding Proteins | 2 | 2013 | 551 | 0.070 |
Why?
|
| von Willebrand Diseases | 1 | 2009 | 55 | 0.070 |
Why?
|
| Cell Line, Tumor | 5 | 2021 | 3708 | 0.070 |
Why?
|
| Glutathione Transferase | 1 | 2008 | 145 | 0.070 |
Why?
|
| Pedigree | 3 | 2020 | 1714 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 1406 | 0.070 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 1519 | 0.070 |
Why?
|
| Gene Rearrangement | 2 | 2013 | 323 | 0.070 |
Why?
|
| Adenoviridae | 1 | 2010 | 586 | 0.070 |
Why?
|
| Infratentorial Neoplasms | 1 | 2007 | 37 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2009 | 195 | 0.070 |
Why?
|
| Nuclear Proteins | 3 | 2014 | 1228 | 0.070 |
Why?
|
| Antigens, Differentiation | 1 | 2007 | 68 | 0.070 |
Why?
|
| Maximum Tolerated Dose | 3 | 2013 | 175 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 620 | 0.060 |
Why?
|
| Lung | 1 | 2015 | 1571 | 0.060 |
Why?
|
| Oligodendroglia | 1 | 2007 | 81 | 0.060 |
Why?
|
| Neurologic Examination | 1 | 2007 | 197 | 0.060 |
Why?
|
| Platelet Aggregation | 3 | 1998 | 104 | 0.060 |
Why?
|
| Choroid | 1 | 2006 | 22 | 0.060 |
Why?
|
| Face | 1 | 2008 | 196 | 0.060 |
Why?
|
| Loss of Heterozygosity | 1 | 2006 | 124 | 0.060 |
Why?
|
| Research | 2 | 2022 | 269 | 0.060 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2006 | 39 | 0.060 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2006 | 52 | 0.060 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2006 | 17 | 0.060 |
Why?
|
| Pulmonary Blastoma | 1 | 2006 | 12 | 0.060 |
Why?
|
| Retreatment | 2 | 2021 | 87 | 0.060 |
Why?
|
| DNA Copy Number Variations | 2 | 2021 | 1027 | 0.060 |
Why?
|
| Postoperative Complications | 3 | 2024 | 3135 | 0.060 |
Why?
|
| Achievement | 1 | 2005 | 32 | 0.060 |
Why?
|
| Androgen Antagonists | 1 | 2026 | 114 | 0.060 |
Why?
|
| Lymphocytes | 2 | 2019 | 359 | 0.060 |
Why?
|
| Optic Nerve | 1 | 2006 | 115 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2008 | 849 | 0.060 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2005 | 45 | 0.060 |
Why?
|
| Genetic Therapy | 2 | 2010 | 726 | 0.060 |
Why?
|
| Pregnancy | 2 | 2021 | 7577 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2009 | 1307 | 0.050 |
Why?
|
| Thalidomide | 1 | 2004 | 41 | 0.050 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 23 | 0.050 |
Why?
|
| Uganda | 1 | 2024 | 94 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 2 | 2007 | 1131 | 0.050 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2004 | 15 | 0.050 |
Why?
|
| Gene Transfer Techniques | 1 | 2005 | 343 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2026 | 338 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2008 | 705 | 0.050 |
Why?
|
| Platelet Count | 3 | 1998 | 140 | 0.050 |
Why?
|
| DNA, Satellite | 1 | 2003 | 15 | 0.050 |
Why?
|
| Genes, Wilms Tumor | 1 | 2022 | 5 | 0.050 |
Why?
|
| Receptors, Androgen | 1 | 2026 | 419 | 0.050 |
Why?
|
| In Vitro Techniques | 4 | 2010 | 824 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 533 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 3 | 2016 | 1746 | 0.050 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2002 | 17 | 0.050 |
Why?
|
| Verbal Learning | 1 | 2022 | 69 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 2 | 2014 | 237 | 0.050 |
Why?
|
| Genome-Wide Association Study | 2 | 2023 | 1840 | 0.050 |
Why?
|
| Phenotype | 3 | 2019 | 4531 | 0.050 |
Why?
|
| AC133 Antigen | 2 | 2014 | 35 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2021 | 14 | 0.040 |
Why?
|
| Age of Onset | 2 | 2020 | 631 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2004 | 364 | 0.040 |
Why?
|
| Cell Differentiation | 2 | 2026 | 1951 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 635 | 0.040 |
Why?
|
| Malawi | 1 | 2023 | 339 | 0.040 |
Why?
|
| Poverty Areas | 1 | 2021 | 36 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 202 | 0.040 |
Why?
|
| Home Nursing | 1 | 2001 | 13 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2017 | 741 | 0.040 |
Why?
|
| Receptor, trkB | 1 | 2021 | 23 | 0.040 |
Why?
|
| Remission Induction | 2 | 1993 | 309 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2021 | 60 | 0.040 |
Why?
|
| Dissection | 1 | 2021 | 59 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2026 | 4693 | 0.040 |
Why?
|
| Growth Hormone | 1 | 2021 | 127 | 0.040 |
Why?
|
| Emotions | 1 | 2024 | 367 | 0.040 |
Why?
|
| Paresis | 1 | 2021 | 34 | 0.040 |
Why?
|
| Fatigue | 1 | 2022 | 199 | 0.040 |
Why?
|
| Causality | 1 | 2021 | 92 | 0.040 |
Why?
|
| SMARCB1 Protein | 1 | 2021 | 42 | 0.040 |
Why?
|
| Hemiplegia | 1 | 2021 | 43 | 0.040 |
Why?
|
| Ovariectomy | 1 | 2001 | 163 | 0.040 |
Why?
|
| Serial Passage | 1 | 2020 | 19 | 0.040 |
Why?
|
| Patient-Specific Modeling | 1 | 2020 | 11 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2006 | 1025 | 0.040 |
Why?
|
| Base Sequence | 4 | 2006 | 2783 | 0.040 |
Why?
|
| Genotype | 2 | 2022 | 2655 | 0.040 |
Why?
|
| Perfusion Imaging | 1 | 2020 | 12 | 0.040 |
Why?
|
| Quinolines | 1 | 2021 | 121 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2021 | 113 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2020 | 83 | 0.040 |
Why?
|
| CpG Islands | 2 | 2016 | 341 | 0.040 |
Why?
|
| Imidazoles | 1 | 2021 | 222 | 0.040 |
Why?
|
| RNA, Transfer | 1 | 2020 | 69 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 45 | 0.040 |
Why?
|
| Proctitis | 1 | 2019 | 6 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2002 | 489 | 0.040 |
Why?
|
| Genome, Human | 1 | 2006 | 1338 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2019 | 52 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 102 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 566 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 445 | 0.040 |
Why?
|
| Birth Weight | 1 | 2021 | 346 | 0.040 |
Why?
|
| Audiometry | 2 | 2013 | 22 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 421 | 0.040 |
Why?
|
| Translocation, Genetic | 3 | 2013 | 350 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2019 | 100 | 0.040 |
Why?
|
| India | 1 | 2019 | 245 | 0.040 |
Why?
|
| S100 Proteins | 1 | 1999 | 40 | 0.040 |
Why?
|
| Urinary Incontinence | 1 | 2019 | 73 | 0.040 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1999 | 27 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 989 | 0.040 |
Why?
|
| Blood Cell Count | 2 | 1995 | 64 | 0.040 |
Why?
|
| Radiation Exposure | 1 | 2019 | 44 | 0.040 |
Why?
|
| Cystectomy | 1 | 2019 | 162 | 0.040 |
Why?
|
| Heredity | 1 | 2018 | 15 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 249 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2020 | 262 | 0.040 |
Why?
|
| Germ Cells | 1 | 2019 | 204 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 295 | 0.030 |
Why?
|
| Karyotyping | 3 | 2004 | 313 | 0.030 |
Why?
|
| Transplantation, Autologous | 2 | 2010 | 269 | 0.030 |
Why?
|
| Mothers | 1 | 2021 | 372 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2019 | 313 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2992 | 0.030 |
Why?
|
| Contrast Media | 1 | 2021 | 492 | 0.030 |
Why?
|
| Mediastinal Neoplasms | 1 | 1998 | 40 | 0.030 |
Why?
|
| Consensus | 1 | 2020 | 530 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2012 | 646 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2021 | 436 | 0.030 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1998 | 62 | 0.030 |
Why?
|
| Cryotherapy | 1 | 2017 | 15 | 0.030 |
Why?
|
| Risk | 1 | 2019 | 739 | 0.030 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2007 | 29 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 771 | 0.030 |
Why?
|
| Heterozygote | 1 | 2019 | 728 | 0.030 |
Why?
|
| Disease Management | 1 | 2021 | 565 | 0.030 |
Why?
|
| Hydrocephalus | 1 | 2020 | 292 | 0.030 |
Why?
|
| Gestational Age | 1 | 2021 | 1235 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2001 | 455 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 22 | 2 | 2013 | 102 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 962 | 0.030 |
Why?
|
| Neutrophils | 1 | 2019 | 369 | 0.030 |
Why?
|
| Subarachnoid Space | 1 | 1996 | 24 | 0.030 |
Why?
|
| Ki-67 Antigen | 2 | 2007 | 106 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2015 | 36 | 0.030 |
Why?
|
| Sample Size | 1 | 2016 | 86 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 1995 | 15 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 1995 | 102 | 0.030 |
Why?
|
| Atlanto-Occipital Joint | 1 | 2015 | 5 | 0.030 |
Why?
|
| Eye | 2 | 2010 | 227 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 195 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 291 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2016 | 140 | 0.030 |
Why?
|
| Necrosis | 2 | 2006 | 195 | 0.030 |
Why?
|
| Blood Platelets | 1 | 1998 | 318 | 0.030 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2014 | 19 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 2008 | 1069 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-4G | 1 | 2014 | 46 | 0.030 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2014 | 23 | 0.030 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2015 | 60 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2014 | 37 | 0.030 |
Why?
|
| Thoracic Vertebrae | 1 | 2015 | 67 | 0.030 |
Why?
|
| United States | 3 | 2019 | 11827 | 0.030 |
Why?
|
| Laser Therapy | 1 | 2017 | 239 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2015 | 225 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 229 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2014 | 60 | 0.030 |
Why?
|
| Bone Marrow | 1 | 1996 | 314 | 0.030 |
Why?
|
| Bronchiolitis | 1 | 1995 | 124 | 0.030 |
Why?
|
| Lumbar Vertebrae | 1 | 2015 | 109 | 0.030 |
Why?
|
| Cervical Vertebrae | 1 | 2015 | 117 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2015 | 259 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 695 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 165 | 0.030 |
Why?
|
| International Agencies | 1 | 2013 | 29 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2015 | 364 | 0.030 |
Why?
|
| Smoothened Receptor | 1 | 2013 | 31 | 0.030 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2013 | 23 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2005 | 334 | 0.020 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2013 | 39 | 0.020 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2013 | 39 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2014 | 714 | 0.020 |
Why?
|
| Mechlorethamine | 1 | 1993 | 7 | 0.020 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2013 | 63 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2013 | 87 | 0.020 |
Why?
|
| Vinblastine | 1 | 1993 | 55 | 0.020 |
Why?
|
| China | 1 | 2013 | 287 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 1219 | 0.020 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 1995 | 233 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 421 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 664 | 0.020 |
Why?
|
| Bleomycin | 1 | 1993 | 112 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 1999 | 579 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2013 | 366 | 0.020 |
Why?
|
| Lymphocyte Activation | 2 | 1991 | 681 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 895 | 0.020 |
Why?
|
| RecQ Helicases | 2 | 2003 | 63 | 0.020 |
Why?
|
| Protein Binding | 2 | 1998 | 1712 | 0.020 |
Why?
|
| Prednisone | 1 | 1993 | 246 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 1994 | 291 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 2012 | 133 | 0.020 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 1992 | 11 | 0.020 |
Why?
|
| Patched Receptors | 1 | 2011 | 27 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 482 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 363 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 1236 | 0.020 |
Why?
|
| Patched-1 Receptor | 1 | 2011 | 38 | 0.020 |
Why?
|
| Hyperbilirubinemia | 1 | 1992 | 41 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 1991 | 151 | 0.020 |
Why?
|
| Blood Component Transfusion | 1 | 1992 | 58 | 0.020 |
Why?
|
| T-Lymphocytes | 2 | 2010 | 1790 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 1319 | 0.020 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 1995 | 385 | 0.020 |
Why?
|
| Plasma | 1 | 1992 | 103 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 1008 | 0.020 |
Why?
|
| Radiometry | 1 | 2011 | 48 | 0.020 |
Why?
|
| Transcriptome | 1 | 2018 | 1141 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1572 | 0.020 |
Why?
|
| Exotoxins | 1 | 1991 | 45 | 0.020 |
Why?
|
| Chemokine CXCL6 | 1 | 2010 | 8 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1991 | 83 | 0.020 |
Why?
|
| Ilium | 1 | 2010 | 23 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3843 | 0.020 |
Why?
|
| Kinetics | 2 | 2009 | 1105 | 0.020 |
Why?
|
| Platelet Factor 4 | 1 | 2010 | 22 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2010 | 36 | 0.020 |
Why?
|
| Hemoglobins | 1 | 1992 | 314 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2010 | 136 | 0.020 |
Why?
|
| HLA-D Antigens | 1 | 1990 | 10 | 0.020 |
Why?
|
| Alleles | 2 | 2006 | 1713 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 580 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2010 | 133 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 303 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2013 | 692 | 0.020 |
Why?
|
| Craniotomy | 1 | 2010 | 102 | 0.020 |
Why?
|
| Aspirin | 1 | 1991 | 216 | 0.020 |
Why?
|
| Binding Sites | 1 | 1991 | 1204 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2001 | 79 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 1018 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 2001 | 92 | 0.020 |
Why?
|
| Genes, cdc | 1 | 2008 | 24 | 0.020 |
Why?
|
| Melanoma | 1 | 1995 | 921 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2008 | 96 | 0.020 |
Why?
|
| Hearing Aids | 1 | 2008 | 32 | 0.020 |
Why?
|
| Oligodendrocyte Transcription Factor 2 | 1 | 2007 | 10 | 0.020 |
Why?
|
| Monocytes | 1 | 1990 | 337 | 0.020 |
Why?
|
| Cryopreservation | 1 | 2008 | 79 | 0.020 |
Why?
|
| Myelin Basic Protein | 1 | 2007 | 68 | 0.020 |
Why?
|
| Oncogenes | 1 | 2008 | 164 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2011 | 558 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2007 | 82 | 0.020 |
Why?
|
| Chronic Disease | 1 | 1992 | 1239 | 0.020 |
Why?
|
| Fatal Outcome | 2 | 1999 | 364 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 976 | 0.020 |
Why?
|
| Osteochondroma | 1 | 2006 | 4 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2010 | 468 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2006 | 66 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 432 | 0.020 |
Why?
|
| Razoxane | 1 | 2005 | 9 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2006 | 107 | 0.010 |
Why?
|
| Transfection | 2 | 2002 | 960 | 0.010 |
Why?
|
| Twist-Related Protein 1 | 1 | 2005 | 35 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 795 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2005 | 255 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 1489 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2006 | 298 | 0.010 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2005 | 107 | 0.010 |
Why?
|
| Cerebellum | 1 | 2009 | 459 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 2005 | 152 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2005 | 232 | 0.010 |
Why?
|
| Family Health | 1 | 2005 | 251 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2006 | 598 | 0.010 |
Why?
|
| Chromosome Painting | 1 | 2004 | 15 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 570 | 0.010 |
Why?
|
| Pathology, Clinical | 1 | 2004 | 20 | 0.010 |
Why?
|
| Atrophy | 1 | 2004 | 251 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 609 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 2004 | 136 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 1860 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 1686 | 0.010 |
Why?
|
| Australia | 1 | 2004 | 176 | 0.010 |
Why?
|
| Chromosome Breakage | 1 | 2004 | 156 | 0.010 |
Why?
|
| Homozygote | 1 | 2005 | 549 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2006 | 544 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2004 | 299 | 0.010 |
Why?
|
| Middle Aged | 3 | 2015 | 28911 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2003 | 208 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2004 | 149 | 0.010 |
Why?
|
| Centromere | 1 | 2003 | 69 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2003 | 68 | 0.010 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2002 | 25 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 436 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 216 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2002 | 97 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2002 | 121 | 0.010 |
Why?
|
| Patient Selection | 1 | 2006 | 726 | 0.010 |
Why?
|
| Cytogenetic Analysis | 1 | 2001 | 79 | 0.010 |
Why?
|
| Introns | 1 | 2002 | 288 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2001 | 77 | 0.010 |
Why?
|
| Omentum | 1 | 2001 | 44 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2001 | 119 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2001 | 96 | 0.010 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2002 | 156 | 0.010 |
Why?
|
| Trisomy | 1 | 2001 | 111 | 0.010 |
Why?
|
| RNA Splicing | 1 | 2002 | 236 | 0.010 |
Why?
|
| Fallopian Tubes | 1 | 2001 | 71 | 0.010 |
Why?
|
| Organ Transplantation | 1 | 2003 | 172 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2005 | 825 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2003 | 577 | 0.010 |
Why?
|
| Age Distribution | 1 | 2001 | 429 | 0.010 |
Why?
|
| Reference Values | 1 | 2001 | 692 | 0.010 |
Why?
|
| Genes, myc | 1 | 1999 | 95 | 0.010 |
Why?
|
| Abdominal Pain | 1 | 2001 | 316 | 0.010 |
Why?
|
| Ristocetin | 1 | 1998 | 8 | 0.010 |
Why?
|
| Adenosine Diphosphate | 1 | 1998 | 50 | 0.010 |
Why?
|
| P-Selectin | 1 | 1998 | 69 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 3616 | 0.010 |
Why?
|
| Sex Factors | 1 | 2001 | 1352 | 0.010 |
Why?
|
| DNA | 1 | 2002 | 1440 | 0.010 |
Why?
|
| Hospitals, Pediatric | 1 | 2001 | 800 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1995 | 314 | 0.010 |
Why?
|
| Detergents | 1 | 1994 | 21 | 0.010 |
Why?
|
| Solvents | 1 | 1994 | 44 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 1994 | 179 | 0.010 |
Why?
|
| Viruses | 1 | 1994 | 118 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1995 | 772 | 0.010 |
Why?
|
| HLA-DR1 Antigen | 1 | 1991 | 1 | 0.010 |
Why?
|
| H-2 Antigens | 1 | 1991 | 25 | 0.010 |
Why?
|
| Staphylococcus | 1 | 1991 | 68 | 0.010 |
Why?
|
| Shock, Septic | 1 | 1990 | 149 | 0.000 |
Why?
|